| Not Yet Recruiting | A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants NCT07532226 | Janssen-Cilag Ltd. | — |
| Recruiting | A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psor NCT07321873 | Janssen Research & Development, LLC | Phase 2 |
| Recruiting | A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting NCT07220824 | Janssen Research & Development, LLC | — |
| Enrolling By Invitation | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participan NCT07223138 | MoonLake Immunotherapeutics AG | Phase 3 |
| Recruiting | Pain in Inflammatory Joint Diseases NCT06718569 | Diakonhjemmet Hospital | — |
| Recruiting | A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis NCT07141004 | Johnson & Johnson Private Limited | Phase 4 |
| Recruiting | Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Dise NCT06842316 | Centre Hospitalier Régional d'Orléans | — |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With NCT06878404 | Janssen Research & Development, LLC | Phase 3 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants NCT06807424 | Janssen Research & Development, LLC | Phase 3 |
| Recruiting | A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants NCT06663332 | Janssen Research & Development, LLC | Phase 3 |
| Recruiting | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response NCT06641089 | MoonLake Immunotherapeutics AG | Phase 3 |
| Active Not Recruiting | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Anti NCT06641076 | MoonLake Immunotherapeutics AG | Phase 3 |
| Terminated | Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis NCT06522035 | Enlivex Therapeutics Ltd. | Phase 1 |
| Not Yet Recruiting | Effectiveness of Digital Rehabilitation (SIMPLI.REHAB) in Hand Arthritis NCT06077890 | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. | N/A |
| Recruiting | Influence of Sodium Intake in spondyLoarthriTes NCT06259890 | Centre Hospitalier Universitaire de Besancon | N/A |
| Recruiting | IMPACT - AndHealth Autoimmune Research Registry NCT05883371 | AndHealth | — |
| Completed | Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis NCT05640245 | MoonLake Immunotherapeutics AG | Phase 2 |
| Completed | Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic D NCT05571696 | Elaine Husni | N/A |
| Withdrawn | A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active P NCT04680676 | Boehringer Ingelheim | Phase 2 |
| Recruiting | Novel Complex Radiodiagnostics of Peripherial Arthropathies NCT05657847 | Semmelweis University | — |
| Terminated | A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis NCT05083078 | Janssen Research & Development, LLC | Phase 1 |
| Completed | A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis NCT05071664 | Janssen Research & Development, LLC | Phase 2 |
| Active Not Recruiting | A Long-term Extension Study of Ustekinumab in Pediatric Participants NCT05092269 | Janssen Research & Development, LLC | Phase 3 |
| Active Not Recruiting | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-T NCT04936308 | Janssen Research & Development, LLC | Phase 3 |
| Active Not Recruiting | A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Ax NCT04929210 | Janssen Research & Development, LLC | Phase 4 |
| Active Not Recruiting | A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis NCT05049798 | Janssen Pharmaceutica N.V., Belgium | — |
| Active Not Recruiting | A Study of Guselkumab in Participants With Active Psoriatic Arthritis NCT04882098 | Janssen Research & Development, LLC | Phase 3 |
| Unknown | PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors NCT04821206 | Liga Panamericana de Asociaciones de Reumatologia (PANLAR) | — |
| Recruiting | Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response. NCT04731831 | Aalborg University Hospital | — |
| Withdrawn | Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis NCT04115020 | Brigham and Women's Hospital | Phase 2 |
| Completed | A Pilot Study of Technetium [99Tc] Methylene Diphosphonate in the Treatment of Psoriatic Arthritis NCT05000086 | Peking Union Medical College Hospital | Phase 4 |
| Completed | A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor NCT03796858 | Janssen Pharmaceutica N.V., Belgium | Phase 3 |
| Completed | WORKWELL: Testing Work Advice for People With Arthritis NCT03942783 | University of Salford | N/A |
| Completed | A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment NCT03828045 | Amgen | — |
| Completed | A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spo NCT03733925 | Johnson & Johnson Private Limited | Phase 4 |
| Completed | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. NCT03747939 | Amgen | Phase 4 |
| Suspended | Central Pain Mechanisms in Patients With Hand-Osteoarthritis, Psoriatic Arthritis and Healthy Controls NCT03703934 | Aalborg University Hospital | — |
| Withdrawn | Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthr NCT03625089 | Chinese University of Hong Kong | N/A |
| Completed | Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis NCT04173039 | Association pour la Recherche Clinique et Immunologique | N/A |
| Completed | Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoria NCT03608657 | Amgen | — |
| Unknown | Fertility Study of Women With Chronic Inflammatory Rheumatism NCT03452735 | University Hospital, Toulouse | — |
| Completed | One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study NCT03662919 | Biogen | — |
| Completed | Low Dose Naltrexone for Chronic Pain From Arthritis NCT03008590 | VA Office of Research and Development | Phase 2 |
| Completed | A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Acti NCT03162796 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Acti NCT03158285 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Stepping Up For Inflammatory Arthritis NCT02912221 | University of Pennsylvania | N/A |
| Completed | A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgi NCT03096990 | Amgen | — |
| Completed | A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands NCT02875184 | Amgen | — |
| Unknown | Ultrasound in Psoriatic Arthritis Treatment NCT03330769 | University of Cagliari | — |
| Completed | BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis NCT02719171 | AbbVie | Phase 2 |
| Completed | Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions NCT03106051 | Amgen | — |
| Unknown | Mechanism of Action of Ustekinumab in Psoriatic Arthritis NCT03565042 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Completed | Psoriatic Arthritis Pathobiology and Its Relationship With Clinical Disease Activity NCT06676176 | Barts & The London NHS Trust | — |
| Completed | MYL-1401A Efficacy and Safety Comparability Study to Humira® NCT02714322 | Mylan Inc. | Phase 3 |
| Completed | 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psori NCT02294227 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? NCT02436785 | University of British Columbia | N/A |
| Completed | Follow-up of Person-centered Care of Young Adults With Rheumatic Disease NCT02402894 | Vastra Gotaland Region | — |
| Completed | A Study of Golimumab in Participants With Active Psoriatic Arthritis NCT02181673 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis NCT02098694 | Norwegian University of Science and Technology | N/A |
| Completed | Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis NCT01976364 | Pfizer | Phase 3 |
| Completed | The DIET Trial - Dietetic Intervention in Psoriatic Arthritis NCT03142503 | Federal University of São Paulo | N/A |
| Completed | Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biol NCT01490450 | CSL Behring | Phase 2 |
| Completed | A Study of RO5310074 in Patients With Psoriatic Arthritis NCT01199809 | Hoffmann-La Roche | Phase 1 |
| Completed | Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis NCT00998829 | Pfizer | — |
| Completed | A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Ar NCT01313858 | Merck Sharp & Dohme LLC | — |
| Completed | Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis NCT01087788 | UCB BIOSCIENCES GmbH | Phase 3 |
| Completed | A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior NCT01077362 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis NCT01009086 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Golimumab Safety and Surveillance Program Using the Ingenix NHI Database NCT01081717 | Janssen Biotech, Inc. | — |
| Terminated | Single Dose PG102 in Patients With Active Psoriatic Arthritis NCT00787137 | PanGenetics UK Limited | Phase 1 |
| Completed | An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arth NCT00760669 | Janssen Korea, Ltd., Korea | — |
| Completed | Study Evaluating the Safety of Enbrel (Etanercept) NCT00683384 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France NCT02886689 | Central Hospital, Nancy, France | — |
| Completed | Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422) NCT00367237 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | PsA Treatment With hOKT3γ1 (Ala-Ala) NCT00239720 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Terminated | Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthri NCT00273858 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840) NCT00727298 | Merck Sharp & Dohme LLC | — |
| Completed | Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumat NCT00293722 | Pfizer | — |
| Completed | Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermato NCT00293709 | Pfizer | — |
| Completed | A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis NCT00265096 | Centocor, Inc. | Phase 3 |
| Completed | Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects NCT00126724 | Targeted Genetics Corporation | Phase 1 / Phase 2 |
| Completed | Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis NCT00161655 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 4 |
| Completed | Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264) NCT00725296 | Merck Sharp & Dohme LLC | — |
| Completed | Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis NCT00938015 | Pfizer | — |
| Terminated | Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis NCT00090129 | EMD Serono | Phase 3 |
| Completed | A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis NCT00051623 | Centocor, Inc. | Phase 3 |
| Completed | Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or NCT00195377 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Biologic Treatment Registry Across Canada NCT00741793 | Janssen Inc. | — |
| Completed | A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis NCT00001422 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |
| Completed | Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions NCT00001291 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | — |